DFF332 as a Single Agent and in Combination With Everolimus & Immuno-Oncology Agents in Advanced/Relapsed Renal Cancer & Other Malignancies
Phase 1 Terminated
40 enrolled
A Study to Learn About How Different Amounts of the Study Medicine PF-07826390 Act in the Body of People With Cancer When Taken Alone or With Other Anti-cancer Medicines.
Phase 1 Terminated
10 enrolled
A Study to Investigate the Safety and Tolerability of Intravenous QEQ278 in Patients With Advanced Solid Tumors
Phase 1 Terminated
30 enrolled
Aldesleukin and Pembrolizumab in Treating Patients With Advanced or Metastatic Kidney Cancer
Phase 1 Terminated
6 enrolled 11 charts
Study of BDC-3042 as Single Agent and in Combination With Cemiplimab in Patients With Advanced Malignancies
Phase 1 Terminated
17 enrolled
A Study to Assess the Safety, Pharmacokinetics, and Efficacy of Intravenous (IV) ABBV-303, as Monotherapy and in Combination With IV Infused Budigalimab (ABBV-181), in Adults With Advanced Solid Tumors
Phase 1 Terminated
27 enrolled
A Study of HFB301001 in Adult Patients With Advanced Solid Tumors
Phase 1 Terminated
31 enrolled
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099318 in Participants With Advanced Solid Tumors
Phase 1 Terminated
105 enrolled
A Phase 1a/1b Study of ACTM-838 in Patients With Advanced Solid Tumors
Phase 1 Terminated
10 enrolled
A Study of PF-07820435 as a Single Agent and in Combination in Participants With Advanced Solid Tumors
Phase 1 Terminated
9 enrolled
Study of PF-07265807 in Participants With Metastatic Solid Tumors.
Phase 1 Terminated
88 enrolled
A Dose-escalation, Dose-finding, and Expansion Study of XL495 in Participants With Locally Advanced or Metastatic Solid Tumors
Phase 1 Terminated
9 enrolled
RAPTOR
Phase 1 Terminated
27 enrolled
Interventional Study of INCB 99280 With Ipilimumab in Participants With Select Solid Tumors
Phase 1 Terminated
8 enrolled
Study of Nanrilkefusp Alfa Alone and With Pembrolizumab in Adult Patients With Advanced/Metastatic Solid Tumors
Phase 1 Terminated
115 enrolled
A Safety and Efficacy Study Evaluating CTX130 in Subjects With Relapsed or Refractory Renal Cell Carcinoma (COBALT-RCC)
Phase 1 Terminated
19 enrolled
A Phase I/Ib Study of NZV930 Alone and in Combination With PDR001 and /or NIR178 in Patients With Advanced Malignancies.
Phase 1 Terminated
127 enrolled
Study of MT-8421 as Monotherapy and in Combination With Nivolumab in Patients With Selected Advanced Solid Cancer Types
Phase 1 Terminated
15 enrolled
PDL1x41BB
Phase 1 Terminated
160 enrolled
Study to Test the Safety and Tolerability of PF-07209960 in Advanced or Metastatic Solid Tumors
Phase 1 Terminated
37 enrolled 32 charts
Study of RO7515629 in Participants With HLA-G Positive Solid Tumors
Phase 1 Terminated
3 enrolled
PF-06952229 Treatment in Adult Patients With Advanced Solid Tumors
Phase 1 Terminated
49 enrolled 33 charts
A Study of Abemaciclib in Combination With Sunitinib in Metastatic Renal Cell Carcinoma
Phase 1 Terminated
3 enrolled
Study of ADCT-301 in Patients With Selected Advanced Solid Tumors
Phase 1 Terminated
78 enrolled 39 charts
Nivolumab + Ipilimumab With Immunostimulatory Embolization for Stage 4 Renal Cell Carcinoma With Unresected Primary
Phase 1 Terminated
1 enrolled
Study of PF-07263689 in Participants With Selected Advanced Solid Tumors
Phase 1 Terminated
13 enrolled 16 charts
A Study of HC-7366 to Establish the Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D)
Phase 1 Terminated
35 enrolled
TORCH
Phase 1 Terminated
10 enrolled
Vaccine Therapy in Treating Patients With Kidney Cancer
Phase 1 Terminated
9 enrolled
FT516 in Combination With Monoclonal Antibodies in Advanced Solid Tumors
Phase 1 Terminated
12 enrolled
FT538 in Combination With Monoclonal Antibodies in Advanced Solid Tumors
Phase 1 Terminated
16 enrolled
Study of Safety and Functional Imaging of cG250 and Sunitinib in Patients With Advanced Renal Cell Carcinoma
Phase 1 Terminated
8 enrolled 18 charts
TiTAN-1: Safety, Proliferation and Persistence of GEN-011 Autologous Cell Therapy
Phase 1 Terminated
49 enrolled
M8891
Phase 1 Terminated
27 enrolled 26 charts
Safety Study of MGD009 in B7-H3-expressing Tumors
Phase 1 Terminated
67 enrolled
sEphB4-HSA Before Surgery in Treating Patients With Bladder Cancer, Prostate Cancer, or Kidney Cancer
Phase 1 Terminated
2 enrolled
HKT288 in Solid Tumors, Including Epithelial Ovarian Cancer and Renal Cell Carcinoma
Phase 1 Terminated
9 enrolled
Nivolumab in Treating Patients With High-Risk Kidney Cancer Before Surgery
Phase 1 Terminated
19 enrolled
MK-3475-031
Phase 1 Terminated
10 enrolled 13 charts
A Study of LY3381916 Alone or in Combination With LY3300054 in Participants With Solid Tumors
Phase 1 Terminated
60 enrolled
A Dose Escalation, Safety and Activity Study of CDX-014 in Patients With Renal Cell Carcinoma and Ovarian Clear Cell Carcinoma
Phase 1 Terminated
16 enrolled
Study of the Pan-DAC Inhibitor AR-42 and Pazopanib in Advanced Sarcoma and Kidney Cancer
Phase 1 Terminated
6 enrolled 12 charts
A Safety Study of SGN-2FF for Patients With Advanced Solid Tumors
Phase 1 Terminated
47 enrolled
A Study of LY2584702 With Erlotinib or Everolimus in Participants With Solid Tumors
Phase 1 Terminated
29 enrolled 19 charts
TLR8 Agonist VTX-2337 and Cyclophosphamide in Treating Patients With Metastatic, Persistent, Recurrent, or Progressive Solid Tumors
Phase 1 Terminated
4 enrolled
A Study of Robatumumab (SCH 717454, MK-7454) in Combination With Different Treatment Regimens in Pediatric Participants With Advanced Solid Tumors (P05883, MK-7454-006)
Phase 1 Terminated
4 enrolled 8 charts
A Study of Varlilumab (Anti-CD27) and Sunitinib in Patients With Metastatic Clear Cell Renal Cell Carcinoma
Phase 1 Terminated
17 enrolled
A Study of Varlilumab and Atezolizumab in Patients With Advanced Cancer
Phase 1 Terminated
18 enrolled
MT2004-30: Tomotherapy for Solid Tumors
Phase 1 Terminated
23 enrolled
Oral Topotecan As A Radiosensitizing Agent In Rectal Cancer
Phase 1 Terminated
26 enrolled